Alvotech (ALVO)

NASDAQ: ALVO · Real-Time Price · USD

5.10

-0.05 (-0.97%)

At close: Nov 28, 2025, 1:00 PM EST

5.13

+0.03 (0.58%)

After-hours: Nov 28, 2025, 4:31 PM EST

Alvotech Employees

Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.

Employees

1,012

Change (1Y)

13

Growth (1Y)

1.30%

Revenue / Employee

$566,551

Profits / Employee

$68,675

Market Cap

1.60B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	1,012	13	1.30%
Dec 31, 2023	999	82	8.94%
Dec 31, 2022	917	133	16.96%
Dec 31, 2021	784	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ALVO News

4 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewsWire
4 days ago - Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - GlobeNewsWire
8 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
15 days ago - Alvotech (ALVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
16 days ago - Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update - GlobeNewsWire
18 days ago - Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO) - GlobeNewsWire
22 days ago - Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO) - GlobeNewsWire
22 days ago - Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA - GlobeNewsWire